ArticleCHEST pulmonary2025
Metabolic Medications and Youth Hospitalizations for Asthma: A Pre-Post Quasi-Experimental Study.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Obesity and metabolic dysregulation can lead to adverse outcomes in people with asthma. We hypothesized that pharmacological treatment of metabolic conditions in youth with asthma is associated with lowered risk of severe asthma exacerbations. Research Question: Is metabolic pharmacotherapy associated with a lower risk of severe asthma exacerbations among children and young adults with metabolic dysregulation? Study Design and Methods: This retrospective, quasi-experimental, longitudinal study examined severe asthma exacerbations (those requiring hospitalization or an emergency department [ED] visit) among youth aged 5-25 years with asthma and a history of a metabolic condition (obesity, diabetes, or hypertension). Definitions and diagnoses were based on documented international classification of diseases (ICD) codes. We compared the odds of severe asthma exacerbations before and after the initiation of metabolic pharmocotheraphy using adjusted piecewise generalized linear mixed models. Results: The cohort consisted of 783 patients, predominantly female (73.7%), white (71.6%), and non-Hispanic (90.4%). Metformin was the most frequently prescribed metabolic medication (75.4%). Before initiating metabolic pharmocotheraphy, the odds of severe asthma exacerbations increased by 29% per year (OR=1.29, 95%CI = 1.12-1.49). Conversely, following the commencement of metabolic pharmacotherapy, the odds of severe asthma exacerbations decreased by 66% per year (OR=0.34, 95%CI = 0.23-0.50), showing a statistically significant and marked difference between the pre- and post-treatment periods. Interpretation: Our findings show that the odds of severe asthma excerbations are substantially lower after the initiation of metabolic pharmacotheraphy, highlighting the positive impact that treatment of metabolic syndromes could have in reducing the risk of severe asthma exacerbations. This underscores the interconnectedness of metabolic and respiratory health and the need for further research into effective treatment strategies for individuals with asthma and obesity-related metabolic conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.